Malignant glioma biology: Role for TGF-β in growth, motility, angiogenesis, and immune escape

Microscopy Research and Technique

Volumn 52, Issue 4, 2001, Pages 401-410

  Platten, Michael ^a,b   Wick, Wolfgang ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Decorin; Immune system; Metalloproteinases; Tranilast; Transforming growth factor

Indexed keywords

CELLS; ENZYME INHIBITION; TUMORS;

ANGIOGENESIS; ANTI-TUMOR IMMUNE; DECORIN; IMMUNE SURVEILLANCE; MALIGNANT GLIOMA; METALLOPROTEINASES; TGF-Β; TRANILAST; TRANSFORMING GROWTH FACTOR-Β; TRANSFORMING GROWTH FACTORS;

CELL CULTURE;

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; METALLOPROTEINASE; METALLOPROTEINASE 2; METALLOPROTEINASE 9; METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INFILTRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; GLIOBLASTOMA; GLIOMA CELL; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TUMOR ESCAPE; TUMOR VASCULARIZATION;

EID: 0035865158     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C     Document Type: Review

References (140)

1. Abe M, Oda N, Sato Y. 1998. Cell-associated activation of latent transforming growth factor-beta by calpain. J Cell Physiol 174:186-193.
2. Ahuja SS, Paliogianni F, Yamada H, Balow JE, Boumpas DT. 1993. Effect of transforming growth factor-beta on early and late activation events in human T cells. J Immunol 150:3109-3118.
3. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. 1993. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 92:2569-2576.
4. Ashkenazi E, Deutsch M, Tirosh R, Weinreb A, Tsukerman A, Brodie C. 1997. A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation. Neuroimmunomodulation 4:49-56.
5. Azuma H, Banno K, Yoshimura T. 1976. Pharmacological properties of N-(dimethoxycinnamoyl) anthranilic acid (N-5′), a new antiatopic agent. Br J Pharmacol 58:483-488.
6. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. 1990. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63:515-524.
7. Bereta J, Bereta M, Coffman FD, Cohen S, Cohen MC. 1992. Inhibition of basal and tumor necrosis factor-enhanced binding of murine tumor cells to murine endothelium by transforming growth factor-beta. J Immunol 148:2932-2940.
8. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med 342:1350-1358.
9. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A. 1989. Immunosuppression and transforming growthfactor in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143:3222-3229.
10. Brooks B, Chapman K, Lawry J, Meager A, Rees RC. 1990. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-β1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production. Clin Exp Immunol 82:583-589.
11. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with the integrin alpha v beta 3. Cell 85:683-693.
12. Brooks WH, Roszman TL, Rogers AS. 1976. Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors. Cancer 37:1869-1873.
13. Brooks WH, Roszman TL, Mahaley MS, Woosley RE. 1977. Immunobiology of primary intracranial tumors: II. Analysis of lymphocyte subpopulations in patients with primary brain tumors. Clin Exp Immunol 29:61-66.
14. Carrel S, De Tribolet N, Gross N. 1982. Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells. Eur J Immunol 12:354-357.
15. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. 1993. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of meth A sarcoma. Cancer Res 53:439-4398.
16. Constam DB, Philipp J, Malipiero UV, Ten Dijke P, Schachner M, Fontana A. 1992. Differential expression of transforming growth factor-beta1, beta2, and beta3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404-1410.
17. Crawford SE, Stellmach V, Murphy-Ullrich J, Ribeiro SMF, Lawler J, Hynes RO, Boivin GP, Bouck N. 1998. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170.
18. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, balmain A, Akhurst AJ. 1996. TGF-beta-1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-542.
19. Czarniecki CW, Chiu HH, Wong GHW, McCabe SM, Palladino MA. 1988. Transforming growth factor-beta1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 140:4217-4223.
20. Czyz M, Cierniewski CS. 1999. Selective Sp1 and Sp3 binding is crucial for activity of the integrin alphaV promotor in cultured endothelial cells. Eur J Biochem 265:638-644.
21. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. 1995. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545-5549.
22. de Groot CJA, Montagne L, Barten AD, Sminia P, van der Valk P. 1999. Expression of transforming growth factor (TGF)-beta 1, beta 2 and beta 3 isoforms and TGF-beta type I and type II receptors in Multiple Sclerosis lesions and human adult astrocyte cultures. J Neuropathol Exp Neurol 58:174-187.
23. Delens N, Torreele E, Savelkool H, De Baetselier P, Bouwens L. 1994. Tumor-derived transforming growth factor-β1 and interleukin-6 are chemotactic for lymphokine-activated killer cells. Int J Cancer 57:696-700.
24. Dix AR, Brooks WH, Roszman TL, Morford LA. 1999. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216-232.
25. Dubois DM, Laprise MH, Blanchette F, Gentry LE, Leduc R. 1995. Processing of transforming growth factor-beta 1 precursor by human furin convertase. J Biol Chem 270:10618-10624.
26. Elliott LH, Brooks WH, Roszman TL. 1984. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132:1208-1215.
27. Elliott L, Brooks W, Roszman T. 1987a. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 78:919-922.
28. Elliott LH, Brooks WH, Roszmann TL. 1987b. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J Neurosurg 67:231-236.
29. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MAJ. 1987. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med 166:571-576.
30. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE. 1996. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93:2909-2914.
31. Fontana A, Frei K, Bodmer S, Hofer E, Schreier MH, Palladino MA, Zinkernagel RM. 1984. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin-2 mediated effects. J Immunol 132: 1837-1844.
32. Fontana A, Frei K, Bodmer S, Hofer E, Schreier MH, Palladino MA, Zinkemagel RM. 1989. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 143:3230-3234.
33. Fukayama J, Miyazawa K, Hamano S, Ujiie A. 1996. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol 74:327-332.
34. Gamble JR, Vadas MA. 1991. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-beta. J Immunol 146:1149-1154.
35. Garden AS, Maor MH, Yung WK, Brunner JM, Woo SY, Moser RP, Lee YY. 1991. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20:99-110.
36. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. 1991. Glioblastoma expression of vitronectin and the alphaVbeta3 integrin: adhesion mechanism for transformed glial cells. J Clin Invest 88:1924-1932.
37. Gold LI, Saxena B, Zagzag B, Miller DC, Koslow M, Brandeis L, Farmer JP. 1992. Increased expression of TGF-beta isoforms by malignant gliomas. J Cell Biochem 16B:123.
38. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, Costa L, Rosenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
39. Hannon GJ, Beach D. 1994. p15/INK4B is a potential effector of TGF-beta-induced. Nature 371:257-261.
40. Helseth E, Unsgaard G, Dalen A, Vik R. 1988. The effects of type beta transforming growth factor on proliferation and epidermal growth factor expression in human glioblastoma line. J Neuro- Oncol 6:269-276.
41. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. 1994. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146-149.
42. Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, Yagita H, Sato K, Okumura O. 1995. Human glioma-derived interleukin-10 inhibits antitumor responses in vitro. Neurosurg 37:1160-1167.
43. Hochberg FH, Pruitt A. 1980. Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911.
44. Horst HA, Scheithauer BW, Kelly PJ, Kovach JS. 1992. Distribution of transforming growth factor-beta1 in human astrocytomas. Hum Pathol 23:1284-1288.
45. Huber D, Fontana A, Bodmer S. 1991. Activation of human platelet-derived latent transforming growth factor-β1 by human glioblas-toma cells. Biochem J 277:165-173.
46. Hunter KE, Sporn MG, Davies AM. 1993. Transforming growth factor-betas inhibit mitogen-stimulated proliferation of astrocytes. Glia 7:203-233.
47. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. 1992. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta1. Cancer Res 52:1386-1392.
48. Isaji M, Aruga N, Naito J, Miyata H. 1994. Inhibition by Tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro. Life Sci 55:287-292.
49. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. 1996. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418-423.
50. Isoe S, Naganuma H, Nakano S, Sasaki A, Satoh E, Nagasaka M, Maeda S, Nukui H. 1998. Resistance to growth inhibition by transforming growth factor beta in malignant glioma cells with functional receptors. J Neurosurg 88:529-534.
51. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W. 1993. The effect of transforming growth factor-beta2-specific phosphorothioate-antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944-951.
52. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Wilson JK, Kinzler KW, Vogelstein B. 1994. Deletion of p15 and p16 genes in brain tumors. Cancer Res 54:6353-6358.
53. Jennings MT, Maciunas RJ, Carver RS, Bascom CC, Juneau P, Misulis K, Moses HL. 1991. TGF-beta1 and TGF-beta2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer 49: 129-139.
54. Jennings MT, Kaariainen IT, Gold LI, Maciunas RJ, Commers PA. 1994. TGF-beta1 and TGF-beta2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors and ependymomas: evidence in support of an autocrine hypothesis. Hum Pathol 25:464-475.
55. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11:415-421.
56. Kägi D, Ledermann B, Bürkl K, Seller P, Odermatt P, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
57. Kasid A, Bell GI, Director EP. 1988. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141:690-698.
58. Kim HM, Lee YM. 1999. Role of TGF-beta1 on the IgE-dependent anaphylaxis reaction. J Immunol 162:4960-4965.
59. Koochekpour S, Merzak A, Pilkington GJ. 1996. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 102:209-15.
60. Krupinski J, Kumar P, Kumar S, Kaluza J. 1996. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke 27:852-857.
61. Kulkarni AB, Karlsson S. 1993. Transforming growth factor-beta1 knockout mice. Am J Pathol 143:3-9.
62. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N. 1989. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor-beta2. J Neurosurg 71:211-217.
63. Lampson LA, Hickey WF. 1986. Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136:4054-4062.
64. Leof EB, Proper JA, Groustin AS, Shipley GD, Dicorletto PE, Moses HL. 1986. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci USA 83:2453-2457.
65. Li JM, Datto MB, Shen X, Hu PPC, Yu Y, Wang XF. 1998. Sp1, but not Sp3, functions to mediated promoter activation by TGF-beta through canonical Sp1 binding sites. Nucl Acids Res 26:2449-2456.
66. Li XF, Takiuchi H, Zou JP, Katagiri T, Yamamoto N, Nagata T, Ono S, Fujiwara H, Hamaoka T. 1993. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function. Jpn J Cancer Res 84:315-325.
67. Liau LM, Fakhrai H, Black KL. 1998. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 20:742-747.
68. Lindholm D, Castren E, Kiefer R, Zafra F, Thoenen H. 1992. Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol 117:395-400.
69. Liu C, Yao J, Mercola D, Adamson E. 2000. The transcription factor EGR-1 directly regulates fibronectin production in human glioblastoma cell line U251. J Biol Chem 275:20315-20323.
70. Lowin B, Hahne M, Mattmann C, Tschopp J. 1994. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 370:650-652.
71. Lyons RM, Gentry LE, Purchio AF, Moses HL. 1990. Mechanisms of activation of latent recombinant transforming growth factor-beta1 by plasmin. J Cell Biol 110:1361-1367.
72. Markowitz S, Wang J, Myeroff L, Parson R, Sun L, Lutterbaugh T, Fan RS, Zborowska A, Kinzler KW, Vogelstein B, Brattain MG, Willson JKV. 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
73. Massagué J. 1998. TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
74. Massagué J. 1990. The transforming growth factor-beta family. Annu Rev Cell Biol 6:597-641.
75. Massagué J, Wotton D. 2000. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745-1754.
76. Massey V, Wallner K 1992. Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395-398.
77. McMahon GA, Dignam JD, Gentry LE. 1996. Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. Biochem J 313:343-351.
78. Merzak A, McCrea S, Koocheckpour S, Pilkington GJ. 1994. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta1. Br J Cancer 70:199-203.
79. Miyake K, Kimura S, Nakanishi M, Hisada A, Hasegawa M, Nagao S, Abe Y. 2000. Transforming growth factor-beta 1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integrin expression. J Neuropathol Exp Neurol 59:18-28.
80. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. 1995. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 118:213-21.
81. Morford LA, Elliot LH, Carlson SL, Brooks WH, Roszman TL. 1997. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415-4425.
82. Morford LA, Dix AR, Brooks WH, Roszman TL. 1999. Apoptotic elimination of peripheral blood T-lymphocytes in patients with primary intracranial tumors. J Neurosurg.
83. Mornex F, Nayel H, Taillandier L. 1993. Radiation hterapy for malignant astrocytomas in adults. Radiother Oncol 27:181-192.
84. Moses HL, Branum EL, Proper JA, Robinson RA. 1981. Transforming growth factor production by chemically transformed cells. Cancer Res 41:2842-2848.
85. Munger J, Huang X, Kawakatsu H, Griffiths M, Dalton S, Wu J, Pittet JF, Kaminski N, Garat C, Matthay M, Rifkin D, Sheppard D. 1999. The integrin alpha V beta 6 binds and activates latent TGF-beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328.
86. Noble NA, Border WA. 1997. Angiotensin II in renal fibrosis: Should TGF- beta rather than blood pressure be the therapeutic target? Semin Nephrol 17:455-466.
87. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engström U, Heldin CH. 1992. Transforming growth factor-beta1, -beta2, and -beta3 secreted by a human glioblastoma cell line. J Biol Chem 267:19482-19488.
88. Ortaldo JR, Mason AT, O'Shea JJ, Smyth MJ, Falk LA, Kennedy ICS, Longo DL, Ruscetti FW. 1991. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3 large granular lymphocyte functions. Regulation of IL-2Rbeta (p75) signal transduction. J Immunol 3791-3798.
89. Paulus W, Tonn J. 1994. Basement membrane invasion of glioma cells mediated by integrin receptors. J Neurosurg 80:515-519.
90. Paulus W, Baur I, Huettner C, Schmaußer B, Roggendorf W, Schlingensiepen H, Brysch W. 1995. Effects of transforming growth factor-beta1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropathol Exp Neurol 54:236-244.
91. Peress NS, Perillo E. 1995. Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brain. J Neuropathol Exp Neurol 54:802-811.
92. Piek E, Westermark U, Kastemar M, Heldin CH, van Zoelen EJ, Nister M, Ten Dijke P. 1999. Expression of transforming growth factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1. Int J Cancer 80:756-763.
93. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. 2000a. Transforming growth factors beta1 (TGF-beta1) and TGF-beta2 promote glioma cell migration via up-regulation of alphaV-beta3 integrin expression. Biochem Biophys Res Commun 268:607-611.
94. Platten M, Wild-Bode C, Wick W, Weller M. 2000b. Tranilast is a novel anti-glioma agent that suppresses migration and abrogates the release of immunosuppressive transforming growth factor (TGF)-beta2. J Cancer Res Clin Oncol 126 (Suppl):R38.
95. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. 1994. p21Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
96. Pratt BM, McPherson JM. 1997. TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev 8:267-292.
97. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschmann T. 1995. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11:409-414.
98. Rich JN, Zhang M, atto MB, Bigner DB, Wang XF. 1999. Transforming growth factor-beta-mediated p15INK4B induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 274:35053-35058.
99. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. 1981. New class of transforming growth factor potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 78:5339-5343.
100. Rook AH, Kehrl JH, Wakefield LM, Roberts AM, Sporn MB, Burlington DB, Lane HC, Fauci AS. 1986. Effects of transforming growth factor beta on the fuctions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-3920.
101. Rooprai HK, Rucklidge GJ, Panou C, Pilkington GJ. 2000. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumor cells. Br J Cancer 82:52-55.
102. Roszman T, Elliott L, Brooks W. 1991. Modulation of T-cell function by gliomas. Immunol Today 12:370-374.
103. 2+-independent T cell-mediated cytotoxicity. J Exp Med 177:195-200.
104. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. 1999. Latent transforming growth factor-beta binding proteins (LTBPs): structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 10:99-117.
105. Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB. 1989. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134:895-902.
106. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. 1997. TGF-beta2 knockout mice have multipe developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124:2656-2670.
107. Sato Y, Rifkin D. 1989. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of latent transforming gowth factor-beta1-like molecule plasmin during co-culture. J Cell Biol 109:309-315.
108. Schwartz RH. 1996. Models of T cell anergy: Is there a common molecular mechanism? J Exp Med 184:1-8.
109. Schwyzer M, Fontana A. 1985. Partial purification and biochemical characterization of a T-cell suppressor factor produced by human glioblastoma cells. J Immunol 134:1003-1009.
110. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschmann T. 1992. Targeted disruption of the mouse transforming growth factor-beta1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
111. Siepl C, Bodmer S, Frei K, MacDonald HR, De Martin R, Hofer E, Fontana A. 1988. The glioblastoma-derived T cell suppressor factor/ transforming growth factor-beta2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593-600.
112. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC. 1991. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol 146:3289-3297.
113. Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann PA, Gulbins E, Dichgans J, Weller M. 1998. Decorin gene-transfer mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 5:1137-1144.
114. Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, Heffner RRJ. 1997. Correlation of endothelin-1 and transforming growth factor beta1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 56:435-439.
115. Suzawa H, Kikuchi S, Arai N, Koda A. 1992. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 60:91-96.
116. Suzumura A, Sawada M, Yamamoto H, Marunouchi T. 1993. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol 151:2150-2158.
117. Tada T, Yabu K, Kobayashi S. 1993. Detection of active form of transforming growth factor-beta in cerebrospinal fluid of patients with glioma. Jpn J Cancer Res 84:544-548.
118. Takiuchi H, Tada T, Li XF, Ogata M, Ikeda T, Fujimoto S, Fujiwara H, Hamaoka T. 1992. Particular types of tmor cells have the capacity to convert transforming growth factor beta from a latent to an active form. Cancer Res 52:5641-5646.
119. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490.
120. Toru-Delbauffe D, Baghdassarian-Chalaye D, Gavaret JM, Courtin F, Pomerance M, Pierre M. 1990. Effects of transforming growth factor-beta 1 on astroglial cells in culture. J Neurochem 54:1056-1061.
121. Tsuzuki T, Izumoto S, Ohnishi T, Hiraga S, Arita N, Hayakawa T. 1998. Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. J Clin Pathol 51:13-17.
122. Tucker RF, Shipley GD, Moses HL. 1984. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 226:705-707.
123. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. 1992. Excessive production of transforming growth factor beta 1 can play a role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochem Biophys Acta 1137:189-196.
124. Uhm JH, Gladson CL, Rao JS. 1999. The role of integrins in the malignant phenotype of gliomas. Front Biosci 4:d188-199.
125. Vergelli V, Mazzanti B, Ballerini C, Gran B, Amaducci L, Massacesi L. 1995. Transforming growth factor-beta1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. J Neurosci Res 40:127-133.
126. Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahl LM, Ellingsworth L, Schmidt JA, Hall G, Roberts AB, Sporn MB. 1988. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 140:3026-3032.
127. Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UE, Mergenhagen SE, Orenstein JM. 1991. Macrophage- and astrocyte-derived transforming growth factor-beta as a mediator of central nervous system dysfunction in acquired immune deficience syndrome. J Exp Med 173:981-991.
128. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA. 1990. Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta. J Exp Med 172:1777-1784.
129. Weller M, Fontana A. 1995. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21:128-151.
130. Weller M, Constam DB, Malpiero U, Fontana A. 1994. Transforming growth factor-beta2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24: 1293-1300.
131. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. 1994. Anti-Fas/APO-1 antibody-mediated apoptosis in cultured human glioma cells. J Clin Invest 94:954-964.
132. Won Y, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. 1999. Tumorigenicity of mouse thymoma is suppressed by soluable type II transforming growth factor beta receptor therapy. Cancer Res 59:1273-1277.
133. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. 1994. Mechanisms of activation of the TGF-beta receptor. Nature 370:34-347.
134. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A. 1987. T cell suppressor factor from human glioblastoma cells is a 12,5-kd protein closely related to transforming growth factor-beta. EMBO J 6:1633-1636.
135. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell S. 1994. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem 116:892-897.
136. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Helden CH, Funa K. 1995. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62:386-392.
137. Yamaguchi Y, Mann DM, Ruoslahti E. 1990. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346:281-284.
138. Zhou GHK, Sechrist GL, Periyasamy S, Brattain MG, Mulder KM. 1995. Transforming growth factor beta isoform-specific differences in interactions with type I and type II transforming growth factor beta receptors. Cancer Res 55:2056-2062.
139. Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, Shuman JD, Coligan JE, Brooks WH, Roszman TL, Shearer GM. 1999. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:4882-4892.
140. Zuber P, Kuppner MC, De Tribolet N. 1988. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18:1623-1626.